Aspira Women's Health Inc. is a leading bio-analytical women's health company dedicated to the development of innovative diagnostic tools specifically for gynecologic diseases. With a strong focus on enhancing early detection and risk assessment, particularly for ovarian cancer, Aspira aims to address significant challenges in women's health diagnostics.
OvaSuite is a comprehensive suite of blood tests designed to aid in the assessment of ovarian cancer risk. It includes specific tests tailored to monitor and evaluate the presence of malignancy in adnexal masses.
Aspira’s products address the critical need for accurate risk assessment and early detection of ovarian cancer, enabling informed clinical management decisions and improving patient outcomes.
The difficulty of early-stage diagnosis for ovarian cancer and gynecologic diseases, leading to delayed treatment options and increased morbidity.